Comparative Pharmacology
Head-to-head clinical analysis: CABERGOLINE versus KYNMOBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABERGOLINE versus KYNMOBI.
CABERGOLINE vs KYNMOBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.
Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.
0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.
Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.
None Documented
None Documented
Clinical Note
moderateCabergoline + Digoxin
"Cabergoline may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCabergoline + Digitoxin
"Cabergoline may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCabergoline + Deslanoside
"Cabergoline may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCabergoline + Acetyldigitoxin
"Cabergoline may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 63-68 hours in healthy subjects, allowing for once- or twice-weekly dosing. In hepatic impairment, half-life may be prolonged.
The terminal elimination half-life of apomorphine is approximately 40 minutes. This short half-life necessitates continuous administration via subcutaneous infusion for sustained clinical effect.
Approximately 60-70% of the dose is excreted in feces (primarily as unchanged drug and metabolites), with about 20-30% excreted renally (mostly as metabolites).
Apomorphine is predominantly metabolized in the liver. Renal excretion accounts for approximately 80% of the dose, with 10% excreted as unchanged drug and 70% as metabolites. Biliary/fecal excretion accounts for the remaining 20%.
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist